An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer

Inclusion criteria

• Patients with histologically proven invasive breast cancer - the primary tumor size is at least 5cm or cytologically proven axillary node metastasis
• no evidence of systemic metastasis pathologically or radiologically
• age at the time of diagnosis between 20 and 70 years
• patients with previously untreated primary breast cancer including chemotherapy
• general performance status with ECOG 0-2
• sufficient hematopoietic function (absolute neutrophil count of ≥ 1,500/mm3, platelet count of ≥ 100,000/mm3, and hemoglobin of ≥ 10 g/dL)
• sufficient renal function (serum creatinine level of ≤ 1.5 mg/dL)
• sufficient liver function (total serum bilirubin level ≤ 1.5 times the upper normal limit; serum AST and ALT levels ≤ 1.5 times the upper normal limit; and serum alkaline phosphatase level ≤ 1.5 times the upper normal limit)
• sufficient cardiac function (normal electrocardiography within 1 month or LVEF>50% by echocardiography or MUGA scan within 3 months)
• patients who agree to enroll this clinical trial and sign the written informed consent voluntarily

Exclusion criteria

• patients with evidence of distant metastases
• patients with other previous malignancy except breast cancer
• pregnant (positive hCG test 1 week before registration) or lactating patient
• uncontrolled serious infection
• patients with psychiatric disease or epilepsy
• patients with clinically severe cardiac disease within 6 months such as atrial or ventricular arrhythmia, congestive heart failure, myocardial infarction, or unstable angina
• male breast cancer
• patients with poor general condition who are not able to understand or sign the written informed consent